Drug Discovery Platform

Our platform gives us the power to identify and develop allosteric modulators that targets disease-related proteins in novel ways

Beactica's fragment-based drug discovery platform is based on state-of-the-art SPR biosensor technology that is augmented by proprietary compound collections, methodology, algorithms and experimental designs. This powerful combination enables us to achieve pioneering goals beyond the expected.

Our approach works also when protein crystallisation is not possible. This means that we can address a wider range of protein targets than possible using structure-based approaches. 

For success examples of applying Beactica's platform technology see here.